Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Esmail M Al-Ezzi"'
Autor:
Esmail M Al-Ezzi, Zachary W Veitch, Samer H Salah, Theodorus H Van der Kwast, Tracy L Stockley, Shamini Selvarajah, Tong Zhang, Srikala S Sridhar, Adrian G Sacher, Nazanin Fallah-Rad, Girish S Kulkarni, Alexandre R Zlotta, Antonio Finelli, Aaron R Hansen
Publikováno v:
PLoS ONE, Vol 16, Iss 12, p e0259272 (2021)
BackgroundNon-schistosomiasis related-squamous cell carcinoma of urinary bladder (NSR-SCCUB) is a rare tumor subtype distinct from urothelial carcinoma (UC). Studies assessing molecular biomarkers in bladder cancer have generally focused on UC, and g
Externí odkaz:
https://doaj.org/article/e3799ed33ecf4271a5cb805e2c0260da
Autor:
Esmail M. Al-Ezzi, Amer Zahralliyali, Aaron R. Hansen, Robert J. Hamilton, Michael Crump, John Kuruvilla, Lori Wood, Lucia Nappi, Christian K. Kollmannsberger, Scott A. North, Eric Winquist, Denis Soulières, Sebastien J. Hotte, Di Maria Jiang
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6166-6176 (2023)
Background: Although metastatic germ cell tumor (GCT) is highly curable with initial cisplatin-based chemotherapy (CT), 20–30% of patients relapse. Salvage CT options include conventional (CDCT) and high dose chemotherapy (HDCT), however definitive
Externí odkaz:
https://doaj.org/article/cdf6575c6dd6426a9ccb2edad31d8e08
Autor:
Jiang, Esmail M. Al-Ezzi, Amer Zahralliyali, Aaron R. Hansen, Robert J. Hamilton, Michael Crump, John Kuruvilla, Lori Wood, Lucia Nappi, Christian K. Kollmannsberger, Scott A. North, Eric Winquist, Denis Soulières, Sebastien J. Hotte, Di Maria
Publikováno v:
Current Oncology; Volume 30; Issue 7; Pages: 6166-6176
Background: Although metastatic germ cell tumor (GCT) is highly curable with initial cisplatin-based chemotherapy (CT), 20–30% of patients relapse. Salvage CT options include conventional (CDCT) and high dose chemotherapy (HDCT), however definitive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::e8b0ceef8457ec32071ed6f5d12ab154
Autor:
Esmail M. Al‐Ezzi, Husam A. Alqaisi, Marco A. J. Iafolla, Lisa Wang, Srikala S. Sridhar, Adrian G. Sacher, Nazanin Fallah‐Rad, Di M. Jiang, Geoffrey A. Watson, Charles N. Catton, Padraig R. Warde, Rob J. Hamilton, Neil E. Fleshner, Alexandre R. Zlotta, Aaron R. Hansen
Publikováno v:
Cancer Medicine, Vol 10, Iss 17, Pp 5775-5782 (2021)
Abstract Background In men with metastatic castration‐resistant prostate cancer (mCRPC) with primarily bone metastases, radium‐223 (223Ra) improves overall survival (OS). However, the selection of 223Ra is not guided by specific validated clinico
Externí odkaz:
https://doaj.org/article/da392819a41c4b0387329a1e9a5afd5b